Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 21, 2009

Merck & Co. Acquires Rights to C. Difficile Drugs from Medarex and MBL for $60M

  • Medarex and Massachusetts Biologic Laboratories (MBL) have out-licensed to Merck & Co. an antibody combination that targets C. difficile in a deal worth over $225 million. Merck gains the worldwide rights to market and further develop the CDA-1 and CDB-1 antibody combination and will pay Medarex and MBL $60 million up front.

    A further $165 million will be paid upon the completion of certain milestones. Medarex and MBL will recieve double-digit royalties and milestones if certain sales levels are met. Pursuant to a prior co-development agreement, Medarex and MBL will divide all payments equally.

    A Phase II multicenter, randomized, double-blind trial showed a reduction in the incidence of infection among 200 patients when compared to those taking a placebo, says Merck. An oral presentation of the results is slated for June 2 at Digestive Disease Week.ADNFCR-2184-ID-19131120-ADNFCR

","DownloadsUrl":"","CompanyUrl":null,"CompanyEmail":null,"IsFavoriteItem":false,"RequestRawUrl":"/gen-news-highlights/merck-co-acquires-rights-to-i-c-difficile-i-drugs-from-medarex-and-mbl-for-60m/53129043?kwrd=Medarex","HasIssueInfo":false,"IssueInfo":null}; var isAuthenticated = 'False';

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.